Found 0 matching trials
Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia PHASE3 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cel...
Show More Location
Hospital Italiano de Buenos Aires
Learn More & Join Trial
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma PHASE2 RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritu...
Show More Location
Comprehensive Cancer Center at University of Alabama at Birmingham
Learn More & Join Trial
Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer PHASE2 Triple-negative breast cancer (TNBC) is a special type of breast cancer, en...
Show More Location
Guangdong general hospital
Learn More & Join Trial
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors PHASE1 This is a Phase 1 dose-finding study of FT-516 in combination with monoclon...
Show More Location
University of Minnesota Masonic Cancer Center
Learn More & Join Trial
AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis PHASE1 One of the possible options for the treatment of MS at present is a high-do...
Show More Location
First Pavlov State Medical University of St. Petersburg
Learn More & Join Trial
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients PHASE3 The purpose of this study is to compare a standard chemotherapy regimen of ...
Show More Location
112 sites UK wide
Treatments Being Tested
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance High dose melphalan therapy and autologous stem cell transplant (intensive pathway only) Learn More & Join Trial
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression PHASE2 Outcomes for patients with severe aplastic anemia (SAA) who are refractory ...
Show More Learn More & Join Trial
Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer PHASE2 Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the importan...
Show More Learn More & Join Trial
Autologous Hematopoietic Stem Cell Transplantation for Neurological Damage Associated With Hereditary Homocysteine Remethylation Disorders NA This study aims to evaluate the safety, feasibility, and preliminary effica...
Show More Location
Institute of Hematology & Blood Diseases Hospital, China
Learn More & Join Trial
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer PHASE1 RATIONALE: Giving chemotherapy before a peripheral stem cell transplant sto...
Show More Location
Multiple Locations
Learn More & Join Trial